Doctors at London's Great
Ormond Street Hospital announced earlier this month the UK's first apparent success in using gene therapy to treat a patient. An 18-month-old boy with sex-linked severe combined immune deficiency (SCID) who was confined to sterile living conditions now shows an immune system that looks normal, the research team announced. It is only the second case of gene therapy reaching this level of success worldwide, and provides a welcome boost to research after a decade of often disappointing and sometimes disastrous results.
Although the patient, Rhys Evans, shows every sign of being normal, there is still a risk he may relapse, making him once again vulnerable to the opportunistic infections that strike someone with a compromised immune system. Alan Thrasher, the consultant paediatric immunologist at the Great Ormond Street Hospital, who carried out the treatment said: "Rhys will be followed up for years and years. Only in the long term will we really be able to compare what we've done to Rhys with our other patients who've been through more conventional transplant procedures."
For the past 20 years the only treatment for such patients has been a bone marrow transplant. So Rhys was transferred from his local hospital in in South Wales to a sterile room at Great Ormond Street, one of the country's leading children's hospitals. Doctors soon began the search for a bone marrow donor, as Rhys did not have a brother or sister to act as a tissue-matched donor. "We were told one day there wasn't a match in the UK, and so looked worldwide," says Mrs Evans. "A potential American donor was found but the next day next day we were given the opportunity for gene therapy," she said.
Bone marrow cells were extracted from the boy's hip and mixed in the lab with a mouse retrovirus vector containing a normal version of the boy's defective gene. The cells were then later transfused back into the patient.
Thrasher said that after the treatment, Rhys now appears to have a normal immune system. "We were enormously relieved. We were ecstatic. We've been working on gene therapy for many We were enormously relieved. We were ecstatic. We've been working on gene therapy for many years in the laboratory and it's great to be able to take that work into the clinic and see some therapeutic success One of the attractions of haemophilia for gene therapy is that a patient only needs to produce very low levels of the missing factor compared with normal levels to restore patients to a much more manageable disease. The team hope to get patients to produce just one per cent of the normal level of clotting factor which would be sufficient to prevent most of the joint damage and bleeding complications of the disease. But haemophilia's attraction for therapy also has a downside. Because it can be treated quite effectively, if inconveniently, with injection of factors, gene therapy experiments raise ethical issues.
However, the team got the go ahead and initial results with three patients injected into thigh muscles with a viral vector containing the gene for the defective clotting factor, proved successful. Within two to three months two patients were producing a sufficient amount of the factor to reduce the number of injections of the clotting factor they needed. But most importantly, none of the patients showed any side effects.
One key aspect of the trial was the type of vector used to carry the gene into the patient's cells. Instead of using adenovirus, which was implicated in Gelsinger's death, the scientists used adeno-associated virus (AAV). Unlike adenovirus, AAV does not appear to stimulate the human immune system.
As more patients were recruited into the trial, the next phase was planned -direct injection into the patient's liver. It is hoped this will result in a significant boost in factor levels. However this part of the trial came to a halt late last year when virus was discovered in the semen of some of the patients.
This raised one of the biggest worries for some about gene therapy: the potential to alter germ line cells. This presents an overriding concern for the regulatory bodies. Norman Nevin, the chairman of GTAC, said that one of the guiding principles on which his committee makes decisions is that there is little or no risk of altering the genes of sperm or eggs.
But further work by the US team found that the viral genes had not entered sperm cells and the virus was eventually cleared from the semen. The US Food and Drug Administration gave the go ahead for the trial to continue earlier this year. And the US agencies are also insisting High and Kay's trial makes regular and detailed analyses to ensure germline alterations are not occurring unwittingly.
Others are now hoping to follow the US lead and also begin trials on haemophilia and other genetic diseases. Haematologist Christine Lee at the Royal Free Hospital in London hopes trials in the UK will be under way within five years.
Studies on new vectors and new routes for the transfer of genes are likely to gain from these latest clinical results. There is no doubt such a dramatic transformation in a patients' condition, in the face of otherwise devastating genetic diseases, will bolster new enthusiasm for research.
